Middle East and Africa hemostats market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

October 2017 | 150 pages | ID: MF656D1D163EN
Data Bridge Market Research

Abstracts

In this report, Middle East and Africa hemostats market is projected to reach USD 134.3 million by 2024 from USD 103.7 million in 2016, growing at a CAGR of 3.2 % in the forecast period 2017 to 2024.

Based on geography, the Middle East and Africa hemostats market is segmented into 5 geographical regions, such as,

• South Africa
• Rest Of Middle East And Africa

Middle East and Africa hemostats market competition by top players including

• Pfizer
• C.R. Bard
• Baxter
• Vascular Solutions, Inc.
• B.Braun Melsungen
• Anika Therapeutics, Inc.
• CryoLife, Inc.
• Hemostasis, LLC
• Johnson & Johnson Services, Inc.
• MedTrade Products Limited.
• Integra LifeSciences Corporation
• HEMOTEC MEDICAL GMBH
• Stryker
• CSL Behring
• Mallinckrodt Pharmaceuticals

The Middle East and Africa hemostats market is segmented on the basis of product type, application, end-user, distribution channel, and geography.

On the basis of product types the Middle East and Africa hemostats market is segmented into five product type which includes thrombin based hemostats, combination agents hemostats, oxidized regeneration cellulose based hemostats, gelatin based hemostats and collagen based segments.

On the basis of application, the Middle East and Africa hemostats market is segmented into wound closure and surgery. The surgery segment dominated the market in 2016.

On the basis of end users, the market is classified into hospitals, clinics, ambulatory centers, community healthcare and others.

On the basis of distribution channel, the Middle East and Africa hemostats market is segmented into direct tenders and

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF MIDDLE EAST AND AFRICA HEMOSTATS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. YEARS CONSIDERED FOR THE STUDY
2.3. CURRENCY AND PRICING
2.4. RESEARCH METHODOLOGY
2.5. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6. SECONDARY SOURCE
2.7. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. CHRONIC CONDITIONS AND AGING POPULATION LEADING TO INCREASE IN NUMBER OF SURGICAL PROCEDURES
  3.1.2. TECHNOLOGICAL ADVANCEMENTS
  3.1.3. INCREASING NUMBER OF MINIMALLY INVASIVE SURGERIES
  3.1.4. IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING HEALTHCARE SPENDING
3.2. RESTRAINTS
  3.2.1. RELUCTANCE OF SURGEONS TOWARDS NEW PRODUCTS
  3.2.2. WEAK REIMBURSEMENT
3.3. OPPORTUNITIES
  3.3.1. UNMET MEDICAL NEEDS
  3.3.2. EMERGING MARKET
3.4. CHALLENGES
  3.4.1. DEVELOPMENT OF SUBSTITUTE PRODUCTS
  3.4.2. LIMITATIONS OF HEMOSTATIC AGENTS IN ACHIEVING HEMOSTASIS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY TYPE

6.1. OVERVIEW
6.2. THROMBIN BASED HEMOSTATS
6.3. COMBINATION AGENT HEMOSTATS
6.4. OXIDIZED REGENERATED CELLULOSE BASED HEMOSTATS
6.5. GELATIN BASED HEMOSTATS
6.6. COLLAGEN BASED HEMOSTATS

7. MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY APPLICATION

7.1. OVERVIEW
7.2. WOUND CLOSURE
7.3. SURGICAL HEMOSTATS

8. MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

8.1. OVERVIEW
  8.1.1. DIRECT TENDERS
  8.1.2. RETAIL

9. MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY END USER

9.1. OVERVIEW
9.2. MIDDLE EAST AND AFRICA HEMOSTATS MARKET: HOSPITALS
9.3. MIDDLE EAST AND AFRICA HEMOSTATS MARKET: AMBULATORY CENTERS
9.4. MIDDLE EAST AND AFRICA HEMOSTATS MARKET: COMMUNITY HEALTHCARE
9.5. MIDDLE EAST AND AFRICA HEMOSTATS MARKET: CLINICS

10. MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY GEOGRAPHY

10.1. MIDDLE EAST AND AFRICA
  10.1.1. SOUTH AFRICA
  10.1.2. REST OF MEA

11. MIDDLE EAST AND AFRICA HEMOSTATS MARKET, COMPANY LANDSCAPE

11.1. COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12. COMPANY PROFILES

12.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC)
  12.1.1. COMPANY OVERVIEW
  12.1.2. REVENUE ANALYSIS
  12.1.3. PRODUCT PORTFOLIO
  12.1.4. RECENT DEVELOPMENTS
12.2. PFIZER
  12.2.1. COMPANY OVERVIEW
  12.2.2. REVENUE ANALYSIS
  12.2.3. PRODUCT PORTFOLIO
  12.2.4. RECENT DEVELOPMENTS
12.3. C R BARD
  12.3.1. COMPANY OVERVIEW
  12.3.2. REVENUE ANALYSIS
  12.3.3. PRODUCT PORTFOLIO
  12.3.4. RECENT DEVELOPMENTS
12.4. BAXTER
  12.4.1. COMPANY OVERVIEW
  12.4.2. REVENUE ANALYSIS
  12.4.3. PRODUCT PORTFOLIO
  12.4.4. RECENT DEVELOPMENTS
12.5. VASCULAR SOLUTIONS, INC (ACQUIRED BY TELEFLEX INCORPORATED)
  12.5.1. COMPANY OVERVIEW
  12.5.2. REVENUE ANALYSIS
  12.5.3. PRODUCT PORTFOLIO
  12.5.4. RECENT DEVELOPMENTS
12.6. B. BRAUN MELSUNGEN AG
  12.6.1. COMPANY OVERVIEW
  12.6.2. REVENUE ANALYSIS
  12.6.3. PRODUCT PORTFOLIO
  12.6.4. RECENT DEVELOPMENTS
12.7. CURAMEDICAL B.V.
  12.7.1. COMPANY OVERVIEW
  12.7.2. COMPANY SNAPSHOT
  12.7.3. PRODUCT PORTFOLIO
  12.7.4. RECENT DEVELOPMENTS
12.8. AXIO BIOSOLUTIONS PRIVATE LIMITED
  12.8.1. COMPANY OVERVIEW
  12.8.2. COMPANY SNAPSHOT
  12.8.3. PRODUCT PORTFOLIO
  12.8.4. RECENT DEVELOPMENTS
12.9. ANIKA THERAPEUTICS, INC.
  12.9.1. COMPANY OVERVIEW
  12.9.2. REVENUE ANALYSIS
  12.9.3. PRODUCT PORTFOLIO
  12.9.4. RECENT DEVELOPMENTS
12.10. AEGIS LIFESCIENCES
  12.10.1. COMPANY OVERVIEW
  12.10.2. REVENUE ANALYSIS
  12.10.3. PRODUCT PORTFOLIO
  12.10.4. RECENT DEVELOPMENTS
12.11. CRYOLIFE, INC.
  12.11.1. COMPANY OVERVIEW
  12.11.2. REVENUE ANALYSIS
  12.11.3. PRODUCT PORTFOLIO
  12.11.4. RECENT DEVELOPMENTS
12.12. GELITA AG
  12.12.1. COMPANY OVERVIEW
  12.12.2. COMPANY SNAPSHOT
  12.12.3. PRODUCT PORTFOLIO
  12.12.4. RECENT DEVELOPMENTS
12.13. HEMOSTASIS, LLC
  12.13.1. COMPANY OVERVIEW
  12.13.2. COMPANY SNAPSHOT
  12.13.3. PRODUCT PORTFOLIO
  12.13.4. RECENT DEVELOPMENTS
12.14. MEDTRADE PRODUCTS LIMITED
  12.14.1. COMPANY OVERVIEW
  12.14.2. COMPANY SNAPSHOT
  12.14.3. PRODUCT PORTFOLIO
  12.14.4. RECENT DEVELOPMENTS
12.15. STRYKER
  12.15.1. COMPANY OVERVIEW
  12.15.2. REVENUE ANALYSIS
  12.15.3. PRODUCT PORTFOLIO
  12.15.4. RECENT DEVELOPMENTS
12.16. ARCH THERAPEUTICS, INC.
  12.16.1. COMPANY OVERVIEW
  12.16.2. REVENUE ANALYSIS
  12.16.3. PRODUCT PORTFOLIO
  12.16.4. RECENT DEVELOPMENTS
12.17. MALLINCKRODT
  12.17.1. COMPANY OVERVIEW
  12.17.2. REVENUE ANALYSIS
  12.17.3. PRODUCT PORTFOLIO
  12.17.4. RECENT DEVELOPMENTS
12.18. ALTAYLAR MEDICAL
  12.18.1. COMPANY OVERVIEW
  12.18.2. COMPANY SNAPSHOT
  12.18.3. PRODUCT PORTFOLIO
  12.18.4. RECENT DEVELOPMENTS
12.19. INTEGRA LIFESCIENCES CORPORATION
  12.19.1. COMPANY OVERVIEW
  12.19.2. REVENUE ANALYSIS
  12.19.3. PRODUCT PORTFOLIO
  12.19.4. RECENT DEVELOPMENTS
12.20. STARCH MEDICAL
  12.20.1. COMPANY OVERVIEW
  12.20.2. COMPANY SNAPSHOT
  12.20.3. PRODUCT PORTFOLIO
  12.20.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

List Of Tables

LIST OF TABLES

TABLE 1 NUMBER OF SURGICAL PROCEDURES (PER 100,000 POPULATION)
TABLE 2 TYPES OF HEMOSTAT PRODUCTS AND MECHANISM
TABLE 3 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA HEMOSTATS APPLICATION MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY END USER, 2015– 2024 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HEMOSTATS S MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 12 SOUTH AFRICA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 13 SOUTH AFRICA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 14 SOUTH AFRICA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 15 SOUTH AFRICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: RESEARCH SNAPSHOT
FIGURE 4 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BOTTOM UP APPROACH
FIGURE 5 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: TOP DOWN APPROACH
FIGURE 6 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN MIDDLE EAST AND AFRICA HEMOSTATS MARKET
FIGURE 8 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: SEGMENTATION
FIGURE 9 MEDICAL ADVANCEMENTS AND INCREASE IN HEMORRAGE CASES ARE EXPECTED TO DRIVE THE MARKET FOR HEMOSTATS IN THE FORECAST PERIOD 2017 TO 2024
FIGURE 10 THROMBIN BASED HEMOSTATS MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE HEMOSTATS MARKET IN 2017 & 2024
FIGURE 11 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BY TYPE, 2016
FIGURE 12 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BY APPLICATION, 2016
FIGURE 13 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BY DISTRIBUTION CHANNEL, 2016
FIGURE 14 MIDDLE EAST AND AFRICA HEMOSTATS MARKET DOMINATED BY HOSPITALS
FIGURE 15 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BY END-USER, 2016
FIGURE 16 MIDDLE EAST AND AFRICA HEMOSTATS MARKET SNAPSHOT (2016)
FIGURE 17 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BY GEOGRAPHY (2016)
FIGURE 18 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: BY COUNTRY (2017)
FIGURE 19 MIDDLE EAST AND AFRICA HEMOSTATS MARKET BY COUNTRY (2016 & 2024)
FIGURE 20 MIDDLE EAST AND AFRICA HEMOSTATS MARKET BY PRODUCT TYPE (2017 & 2024)
FIGURE 21 MIDDLE EAST AND AFRICA HEMOSTATS MARKET: COMPANY SHARE 2016 (%)